{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:34:18Z","timestamp":1793838858093,"version":"4.6.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974256"],"award-info":[{"award-number":["81974256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173870"],"award-info":[{"award-number":["82173870"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002424"],"award-info":[{"award-number":["82002424"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272874"],"award-info":[{"award-number":["82272874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67365-5","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T03:14:34Z","timestamp":1765682074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaolu","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaorui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-4342","authenticated-orcid":false,"given":"Jingfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-2768","authenticated-orcid":false,"given":"Shengping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-126X","authenticated-orcid":false,"given":"Deshui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-5326","authenticated-orcid":false,"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4019-4922","authenticated-orcid":false,"given":"Baokun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"67365_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"67365_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"67365_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf2947","volume":"14","author":"P Sharma","year":"2022","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint therapy: Forging ahead. Sci. Transl. Med. 14, eadf2947 (2022).","journal-title":"Sci. Transl. Med."},{"key":"67365_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838\u2013857 (2021).","journal-title":"Cancer Discov."},{"key":"67365_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361\u2013375 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"67365_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"67365_CR7","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"67365_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan, R. J. & Weber, J. S. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat. Rev. Drug Discov. 21, 495\u2013508 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67365_CR9","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf, D. et al. Pooled analysis of long-term survival data from Phase II and Phase III Trials of Ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889\u20131894 (2015).","journal-title":"J. Clin. Oncol."},{"key":"67365_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"67365_CR11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"67365_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N. Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"N. Engl. J. Med."},{"key":"67365_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"67365_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"CE Rudd","year":"2009","unstructured":"Rudd, C. E., Taylor, A. & Schneider, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229, 12\u201326 (2009).","journal-title":"Immunol. Rev."},{"key":"67365_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imm.13343","volume":"164","author":"D Janman","year":"2021","unstructured":"Janman, D. et al. Regulation of CTLA-4 recycling by LRBA and Rab11. Immunology 164, 106\u2013119 (2021).","journal-title":"Immunology"},{"key":"67365_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","volume":"349","author":"B Lo","year":"2015","unstructured":"Lo, B. et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349, 436\u2013440 (2015).","journal-title":"Science"},{"key":"67365_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","volume":"349","author":"B Lo","year":"2015","unstructured":"Lo, B. et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349, 436\u2013440 (2015).","journal-title":"Science"},{"key":"67365_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.25100\/cm.v49i3.3802","volume":"49","author":"C Martinez Jaramillo","year":"2018","unstructured":"Martinez Jaramillo, C. & Trujillo-Vargas, C. M. LRBA in the endomembrane system. Colomb. Med. 49, 236\u2013243 (2018).","journal-title":"Colomb. Med."},{"key":"67365_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10875-015-0224-7","volume":"36","author":"OK Alkhairy","year":"2016","unstructured":"Alkhairy, O. K. et al. Spectrum of Phenotypes Associated with Mutations in LRBA. J. Clin. Immunol. 36, 33\u201345 (2016).","journal-title":"J. Clin. Immunol."},{"key":"67365_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/cei.13600","volume":"205","author":"M Jamee","year":"2021","unstructured":"Jamee, M. et al. Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review. Clin. Exp. Immunol. 205, 28\u201343 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"67365_CR21","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jaip.2019.04.011","volume":"7","author":"S Habibi","year":"2019","unstructured":"Habibi, S. et al. Clinical, Immunologic, and Molecular Spectrum of Patients with LPS-Responsive Beige-Like Anchor Protein Deficiency: A Systematic Review. J. Allergy Clin. Immunol. Pract. 7, 2379\u20132386.e2375 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"67365_CR22","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.jaip.2019.06.011","volume":"7","author":"A Kiykim","year":"2019","unstructured":"Kiykim, A. et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J. Allergy Clin. Immunol. Pract. 7, 2790\u20132800.e2715 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"67365_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan, B., Halliday, N. & Sansom, D. M. CTLA-4: a moving target in immunotherapy. Blood 131, 58\u201367 (2018).","journal-title":"Blood"},{"key":"67365_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ni0702-611","volume":"3","author":"JG Egen","year":"2002","unstructured":"Egen, J. G., Kuhns, M. S. & Allison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611\u2013618 (2002).","journal-title":"Nat. Immunol."},{"key":"67365_CR25","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. https:\/\/doi.org\/10.1038\/s41422-019-0184-1 (2019).","DOI":"10.1038\/s41422-019-0184-1"},{"key":"67365_CR26","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y","volume":"29","author":"G Magistrelli","year":"1999","unstructured":"Magistrelli, G. et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29, 3596\u20133602 (1999).","journal-title":"Eur. J. Immunol."},{"key":"67365_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/cimm.2000.1649","volume":"201","author":"MK Oaks","year":"2000","unstructured":"Oaks, M. K. et al. A native soluble form of CTLA-4. Cell Immunol. 201, 144\u2013153 (2000).","journal-title":"Cell Immunol."},{"key":"67365_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"F Arce Vargas","year":"2018","unstructured":"Arce Vargas, F. et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell 33, 649\u2013663.e644 (2018).","journal-title":"Cancer Cell"},{"key":"67365_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"67365_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170, 1120\u20131133.e1117 (2017).","journal-title":"Cell"},{"key":"67365_CR31","doi-asserted-by":"publisher","first-page":"e70352","DOI":"10.1371\/journal.pone.0070352","volume":"8","author":"AK Mittal","year":"2013","unstructured":"Mittal, A. K. et al. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. PloS one 8, e70352 (2013).","journal-title":"PloS one"},{"key":"67365_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/biomethods\/bpac024","volume":"7","author":"JD Greenlee","year":"2022","unstructured":"Greenlee, J. D. & King, M. R. A syngeneic MC38 orthotopic mouse model of colorectal cancer metastasis. Biol. Methods Protoc. 7, bpac024 (2022).","journal-title":"Biol. Methods Protoc."},{"key":"67365_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-019-6344-3","volume":"21","author":"W Zhong","year":"2020","unstructured":"Zhong, W. et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics 21, 2 (2020).","journal-title":"BMC Genomics"},{"key":"67365_CR34","doi-asserted-by":"publisher","unstructured":"Zhou, Y. et al. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J. Exp. Med. 220, https:\/\/doi.org\/10.1084\/jem.20221333 (2023).","DOI":"10.1084\/jem.20221333"},{"key":"67365_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428\u2013432 (2019).","journal-title":"Nature"},{"key":"67365_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1073\/pnas.1712901115","volume":"115","author":"F Wang","year":"2018","unstructured":"Wang, F., Yin, Q., Chen, L. & Davis, M. M. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc. Natl. Acad. Sci. USA 115, 157\u2013161 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67365_CR37","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3389\/fimmu.2019.01235","volume":"10","author":"T Wang","year":"2019","unstructured":"Wang, T. et al. Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. Front. Immunol. 10, 1235 (2019).","journal-title":"Front. Immunol."},{"key":"67365_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12922","volume":"92","author":"NC Moreno-Corona","year":"2020","unstructured":"Moreno-Corona, N. C. et al. Lipopolysaccharide-responsive beige-like anchor acts as a cAMP-dependent protein kinase anchoring protein in B cells. Scand. J. Immunol. 92, e12922 (2020).","journal-title":"Scand. J. Immunol."},{"key":"67365_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67365_CR40","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/2159-8290.CD-22-0301","volume":"12","author":"C Capparelli","year":"2022","unstructured":"Capparelli, C. & Aplin, A. E. Packing a Punch against PD-L1. Cancer Discov. 12, 1413\u20131415 (2022).","journal-title":"Cancer Discov."},{"key":"67365_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12721","volume":"287","author":"N Mitsuiki","year":"2019","unstructured":"Mitsuiki, N., Schwab, C. & Grimbacher, B. What did we learn from CTLA-4 insufficiency on the human immune system?. Immunol. Rev. 287, 33\u201349 (2019).","journal-title":"Immunol. Rev."},{"key":"67365_CR42","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","volume":"149","author":"D Egg","year":"2022","unstructured":"Egg, D. et al. Therapeutic options for CTLA-4 insufficiency. J. Allergy Clin. Immunol. 149, 736\u2013746 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"67365_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bj.2021.04.005","volume":"44","author":"L Gamez-Diaz","year":"2021","unstructured":"Gamez-Diaz, L. & Grimbacher, B. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes. Biomed. J. 44, 400\u2013411 (2021).","journal-title":"Biomed. J."},{"key":"67365_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12997","volume":"190","author":"N Verma","year":"2017","unstructured":"Verma, N., Burns, S. O., Walker, L. S. K. & Sansom, D. M. Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. Clin. Exp. Immunol. 190, 1\u20137 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"67365_CR45","doi-asserted-by":"publisher","unstructured":"Snyder, A. et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1406498 (2014).","DOI":"10.1056\/NEJMoa1406498"},{"key":"67365_CR46","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","volume":"3","author":"I Yofe","year":"2022","unstructured":"Yofe, I. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcgammaR engagement and type I interferon signaling. Nat. Cancer 3, 1336\u20131350 (2022).","journal-title":"Nat. Cancer"},{"key":"67365_CR47","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"67365_CR48","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233\u20131238 (2019).","journal-title":"Clin. Cancer Res."},{"key":"67365_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-019-0751-1","volume":"7","author":"B He","year":"2019","unstructured":"He, B. et al. Antibiotic-modulated microbiome suppresses lethal inflammation and prolongs lifespan in Treg-deficient mice. Microbiome 7, 145 (2019).","journal-title":"Microbiome"},{"key":"67365_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1084\/jem.20160961","volume":"214","author":"B He","year":"2017","unstructured":"He, B. et al. Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency-induced autoimmunity via adenosine A2A receptors. J. Exp. Med. 214, 107\u2013123 (2017).","journal-title":"J. Exp. Med."},{"key":"67365_CR51","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3899\/jrheum.190678","volume":"47","author":"LN Dahal","year":"2020","unstructured":"Dahal, L. N., Barker, R. N. & Ward, F. J. The Soluble Isoform of CTLA-4 Correlates with Interferon-alpha Activity in Systemic Lupus Erythematosus. J. Rheumatol. 47, 302\u2013304 (2020).","journal-title":"J. Rheumatol."},{"key":"67365_CR52","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.it.2018.08.004","volume":"39","author":"LN Dahal","year":"2018","unstructured":"Dahal, L. N., Schwarz, H. & Ward, F. J. Hiding in plain sight: soluble immunomodulatory receptors. Trends Immunol. 39, 771\u2013774 (2018).","journal-title":"Trends Immunol."},{"key":"67365_CR53","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/eji.201242529","volume":"43","author":"FJ Ward","year":"2013","unstructured":"Ward, F. J. et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur. J. Immunol. 43, 1274\u20131285 (2013).","journal-title":"Eur. J. Immunol."},{"key":"67365_CR54","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.immuni.2025.03.004","volume":"58","author":"M Osaki","year":"2025","unstructured":"Osaki, M. & Sakaguchi, S. Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. Immunity 58, 889\u2013908.e813 (2025).","journal-title":"Immunity"},{"key":"67365_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ymthe.2023.11.028","volume":"32","author":"PT Kennedy","year":"2024","unstructured":"Kennedy, P. T. et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol. Ther. 32, 457\u2013468 (2024).","journal-title":"Mol. Ther."},{"key":"67365_CR56","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jlb.65.1.102","volume":"65","author":"R Kumar","year":"1999","unstructured":"Kumar, R., Yoneda, J., Fidler, I. J. & Dong, Z. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J. Leukoc. Biol. 65, 102\u2013108 (1999).","journal-title":"J. Leukoc. Biol."},{"key":"67365_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33116-z","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. Nat. Commun. 13, 5413 (2022).","journal-title":"Nat. Commun."},{"key":"67365_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100297","volume":"2","author":"H Kasashima","year":"2021","unstructured":"Kasashima, H. et al. Mouse model of colorectal cancer: orthotopic co-implantation of tumor and stroma cells in cecum and rectum. STAR Protoc. 2, 100297 (2021).","journal-title":"STAR Protoc."},{"key":"67365_CR59","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/acschembio.5b00753","volume":"11","author":"AS Dixon","year":"2016","unstructured":"Dixon, A. S. et al. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chem. Biol. 11, 400\u2013408 (2016).","journal-title":"ACS Chem. Biol."},{"key":"67365_CR60","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nmeth.2170","volume":"9","author":"KC Cheng","year":"2012","unstructured":"Cheng, K. C. & Inglese, J. A coincidence reporter-gene system for high-throughput screening. Nat. Methods 9, 937 (2012).","journal-title":"Nat. Methods"},{"key":"67365_CR61","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"67365_CR62","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"67365_CR63","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1053\/j.gastro.2009.11.005","volume":"138","author":"JJ Smith","year":"2010","unstructured":"Smith, J. J. et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138, 958\u2013968 (2010).","journal-title":"Gastroenterology"},{"key":"67365_CR64","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"67365_CR65","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ebiom.2019.06.033","volume":"45","author":"NS Nunes","year":"2019","unstructured":"Nunes, N. S. et al. Therapeutic ultrasound attenuates DSS-induced colitis through the cholinergic anti-inflammatory pathway. EBioMedicine 45, 495\u2013510 (2019).","journal-title":"EBioMedicine"},{"key":"67365_CR66","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.cell.2019.10.027","volume":"179","author":"B Huang","year":"2019","unstructured":"Huang, B. et al. Mucosal profiling of pediatric-onset Colitis and IBD reveals common pathogenics and therapeutic pathways. Cell 179, 1160\u20131176.e1124 (2019).","journal-title":"Cell"},{"key":"67365_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","volume":"565","author":"JJ Ishizuka","year":"2019","unstructured":"Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43\u201348 (2019).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67365-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:08:15Z","timestamp":1769216895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67365-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67365"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67365-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}